Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

被引：39

作者：

Lim, DH ^{[1
]}

Park, YS ^{[1
]}

Park, BB ^{[1
]}

Ji, SH ^{[1
]}

Lee, J ^{[1
]}

Park, KW ^{[1
]}

Kang, JH ^{[1
]}

Lee, SH ^{[1
]}

Park, JO ^{[1
]}

Kim, K ^{[1
]}

Kim, WS ^{[1
]}

Jung, CW ^{[1
]}

Im, YH ^{[1
]}

Kang, WK ^{[1
]}

Park, K ^{[1
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul 135710, South Korea

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2005年 / 56卷 / 01期

关键词：

capecitabine; mitomycin-C; advanced colorectal cancer; third-line chemotherapy;

D O I：

10.1007/s00280-004-0963-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine ( Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid ( FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP). Patients and methods: A total of 21 patients (M/F 16/5, median age 60.0 years) with advanced colorectal cancer, all of whom had developed progressive disease while receiving or within 6 months of discontinuing two sequential chemotherapy lines with 5-FU, FA and CPT-11 or 5-FU, FA and L-OHP, were accrued to this study. At the time of their relapse or progression, cytotoxic chemotherapy, consisting of intravenous MMC 7 mg/m(2) on therapeutic day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1 - 14, was initiated. After rest for 7 days, capecitabine 1000 mg/m(2) twice daily was administered on days 22 - 35 followed by 7 days rest. Treatment courses were repeated every 6 weeks unless there was evidence of progressive disease, unacceptable toxicity or patient refusal of treatment. Results: All the patients were assessable for toxicity and 19 for response. The median number cycles of chemotherapy was two ( range one to four). Only 1 patient (4.8%) had a partial response, 4 patients (19.0%) had stable disease, and 14 patients (66.7%) progressed. The median follow-up period was 7.3 months and median time to progression was 2.6 months. The median overall survival was 6.8 months. No toxic deaths occurred. Toxicities of third-line treatment were mild and manageable. As NCI/ NIH common toxicity criteria, grade 3/4 anemia, neutropenia and thrombocytopenia occurred in two, one and one patients, respectively. Conclusion: Our findings suggest that the combination of MMC and capecitabine in patients with advanced colorectal cancer pretreated with combination regimens including 5-FU, FA and CPT-11 or 5-FU, FA and L-OHP is safe. However, this regimen had a poor response rate and no definitive contribution to increasing patients' overall survival time. Further evaluation of other salvage regimens seems to be warranted.

引用

页码：10 / 14

页数：5

共 26 条

[1] CYTARABINE AND CISPLATIN AS SALVAGE THERAPY IN PATIENTS WITH METASTATIC COLORECTAL-CANCER WHO FAILED 5-FLUOROURACIL PLUS FOLINIC ACID REGIMEN [J].